Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 5/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2751201 | 0.81 | TSHR (0.33) | TSHR | |
| SCHEMBL69540 | 0.81 | KDR (0.40) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL4867372 | 0.79 | MAP4K4 (0.47) | DYRK3CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL9955273 | 0.79 | HSD17B1 (0.45) | IDO1NOTUMTAAR1CHRNB4CHRNA3 | |
| SCHEMBL2897272 | 0.79 | IDO1 (0.41) | IDO1NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL2750648 | 0.76 | AHR (0.46) | IDO1NPC1RAB9ANOTUMCYP1B1 | |
| SCHEMBL17028871 | 0.76 | IDO1 (0.46) | IDO1DYRK3CCNT1CCNA2CDK2 | |
| SCHEMBL500354 | 0.75 | DYRK1A (0.47) | TDO2DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2750867 | 0.73 | HSD17B1 (0.40) | NPC1RAB9ANOTUMCYP1A2 | |
| SCHEMBL2753459 | 0.72 | FGFR1 (0.35) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655307-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | Givaudan SA (CH) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085287-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | GIVAUDAN SA (CH) | 2012-06-28 | — | — | WO | claimed |
| WO-2015124606-A1 | N-SUBSTITUTED IMINO HETEROCYCLIC COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| CN-102014900-B | Method of treating cancer using a neuropeptide Y5R (NPY5R) antagonist | UNIV HEALTH NETWORK | 2014-04-02 | — | — | CN | disclosed |
| EP-2655307-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | Givaudan SA (CH) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085287-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | GIVAUDAN SA (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK | 2011-05-12 | — | — | US | disclosed |
| CN-102014900-A | Method of treating cancer using a neuropeptide Y5R (NPY5R) antagonist | UNIV HEALTH NETWORK | 2011-04-13 | — | — | CN | disclosed |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | MSD K.K. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6462053-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM DISORDERS AND METABOLIC DISEASES; HYPERTENSION, NEPHROPATHY, HEART DISEASE, VASOSPASM, ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| CN-1370168-A | Novel spiro compounds | BANYU PHARMA CO LTD (JP) | 2002-09-18 | — | — | CN | disclosed |
| EP-1204663-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | BACE1 489/4885IDO1 501/4885TDO2 1250/4885 |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | NPY5R, NPY1R, SSTR5 | BACE1 3376/4885IDO1 1415/4885TDO2 1423/4885 |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY4R | BACE1 518/4885IDO1 397/4885TDO2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.